Literature DB >> 28331955

Reply to: Predicting the outcome of peptide receptor radionuclide therapy in neuroendocrine tumors: the importance of dual-tracer imaging.

Giovanni Paganelli1, Maddalena Sansovini2, Emanuela Scarpi3.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28331955     DOI: 10.1007/s00259-017-3682-8

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


× No keyword cloud information.
  3 in total

1.  Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors.

Authors:  Jonathan Strosberg; Ghassan El-Haddad; Edward Wolin; Andrew Hendifar; James Yao; Beth Chasen; Erik Mittra; Pamela L Kunz; Matthew H Kulke; Heather Jacene; David Bushnell; Thomas M O'Dorisio; Richard P Baum; Harshad R Kulkarni; Martyn Caplin; Rachida Lebtahi; Timothy Hobday; Ebrahim Delpassand; Eric Van Cutsem; Al Benson; Rajaventhan Srirajaskanthan; Marianne Pavel; Jaime Mora; Jordan Berlin; Enrique Grande; Nicholas Reed; Ettore Seregni; Kjell Öberg; Maribel Lopera Sierra; Paola Santoro; Thomas Thevenet; Jack L Erion; Philippe Ruszniewski; Dik Kwekkeboom; Eric Krenning
Journal:  N Engl J Med       Date:  2017-01-12       Impact factor: 91.245

2.  SUV of [68Ga]DOTATOC-PET/CT Predicts Response Probability of PRRT in Neuroendocrine Tumors.

Authors:  C Kratochwil; M Stefanova; E Mavriopoulou; T Holland-Letz; A Dimitrakopoulou-Strauss; A Afshar-Oromieh; W Mier; U Haberkorn; F L Giesel
Journal:  Mol Imaging Biol       Date:  2015-06       Impact factor: 3.488

3.  Long-term follow-up and role of FDG PET in advanced pancreatic neuroendocrine patients treated with 177Lu-D OTATATE.

Authors:  Maddalena Sansovini; Stefano Severi; Annarita Ianniello; Silvia Nicolini; Lorenzo Fantini; Emilio Mezzenga; Fabio Ferroni; Emanuela Scarpi; Manuela Monti; Alberto Bongiovanni; Sara Cingarlini; Chiara Maria Grana; Lisa Bodei; Giovanni Paganelli
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-10-04       Impact factor: 9.236

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.